Malnutrition is an acutely growing public health concern in the U.S., with over 20% predicted to be malnourished by the year 2030. This study aims to analyze disparities in malnutrition‐related mortalities in the United States from 1999 to 2023. A descriptive study using data from the CDC WONDER database was conducted to examine trends and disparities in malnutrition‐related deaths in adults aged 55–85 years and older. The study classified deaths by age, gender, race, place of death, and urban–rural classification. Age‐adjusted mortality rates (AAMRs) and crude mortality rates per 100,000 population were estimated, and Joinpoint regression analysis was applied to identify annual percent changes (APCs) and average annual percent changes (AAPCs). From 1999 to 2023, 158,117 deaths due to malnutrition were recorded among individuals aged 55 and above. Initial trends showed a decline with an APC of −8.38% from 1999 to 2006, followed by a significant rise from 2013 to 2021 with an APC of 22.51%. The oldest age group showed the highest annual rise of 5.74%. Gender‐specific trends revealed a steep rise in malnutrition‐related deaths for both males and females from 2013 to 2023. Racial disparities showed significant increases in mortality rates among White individuals, with an AAPC of 5.91%. The study reveals a significant resurgence of malnutrition‐related mortality among older adults in the U.S. after years of decline, highlighting the need for targeted public health interventions. Geographical, gender‐specific, and racial disparities suggest systemic healthcare issues that require gender‐sensitive and culturally appropriate nutritional screening and management strategies.

Platelet‐rich plasma (PRP) therapy, while widely utilized for its favorable safety profile, carries a recognized risk of catastrophic, irreversible vision loss, traditionally attributed to iatrogenic vascular embolization following facial injections. We present the first documented case of reversible , subacute vision loss following PRP injections to the scalp , a finding that fundamentally challenges this established paradigm. A 22‐year‐old female presented with unilateral central scotomas one month post‐treatment, with investigations revealing macular edema and an incidental, non‐compressive pituitary microadenoma. In contrast to direct embolic occlusion, we postulate a novel pathophysiological mechanism: a systemic surge of PRP‐derived growth factors (e.g., VEGF, PDGF) triggered a transient, steroid‐responsive inflammatory or microvascular event in a pre‐sensitized neurovascular environment. The patient achieved complete visual recovery following high‐dose corticosteroid therapy, supporting an inflammatory etiology. This case serves as an unequivocal clinical directive that the risk of severe ocular complications from PRP is not confined to facial injections and can manifest systemically. It is imperative that the paradigm of PRP‐related risk be expanded and informed consent protocols revised to reflect the potential for inflammatory and microvascular sequelae, irrespective of the injection site.

Sporadic cervicothoracic dumbbell neurofibromas are rare and surgically challenging when large. A 44-year-old male presented with left cervical swelling, cervicobrachial pain, and C8–T1 deficits with hypothenar atrophy. Magnetic resonance imaging revealed a 6.4 × 6.6 × 11 cm C4–D3 dumbbell mass without invasion. A single-stage posterior C6–D1 laminectomy with microsurgical excision and Cavitron Ultrasonic Surgical Aspirator–assisted debulking achieved complete resection. Postoperatively, pain resolved with marked neurological recovery. Histopathology confirmed WHO Grade I neurofibroma. This case shows that even giant lesions can be safely managed with meticulous microsurgical planning.